TABLE 2.
Performance differences for cognitive tasks for each drug challenge by treatment type
| Cognitive construct | Task | Dependent variable | Treatment | MECA 20 mg + PLC | SCOP 2.5 μg/kg + PLC | SCOP 2.5 μg/kg + MECA 10 mg |
|---|---|---|---|---|---|---|
| Arousal & attention | CFF | Ascending (Hz)a | E2 | −0.337 (2.5) | −0.91 (3.75) | −3.48 (7.6) |
| PLC | 1.237 (1.8) | 0.32 (2.29) | 0.12 (2.0) | |||
| Descending (Hz) | E2 | −0.642 (2.5) | −2.1 (3.54) | −3.7 (4.3) | ||
| PLC | −0.2 (2.8) | −1.96 (3.1) | −3.2 (2.7) | |||
| CRT | Total RT (ms) | E2 | 51.26 (53.1) | 62.6 (81.98) | 110.47 (90.57) | |
| PLC | 51.02 (40.6) | 51.7 (87.1) | 78.8 (68.6) | |||
| Recognition RT (ms)b | E2 | 15 (24.27) | 36.4 (46.5) | 63.11 (46.7) | ||
| PLC | 9.5 (36.5) | 20.16 (41.9) | 31.8 (41.01) | |||
| Motor RT (ms) | E2 | 37.76 (43.7) | 26.6 (49.4) | 47.37 (54.2) | ||
| PLC | 35.66 (41.8) | 27.4 (55.6) | 40.4 (48.9) | |||
| Memory | N-back | 0-Back accuracy (d’) | E2 | 0.32 (1.1) | −0.47 (1.31) | −0.995 (1.76) |
| PLC | −0.24 (1.56) | −1.21 (2.14) | −0.927 (1.75) | |||
| 1-Back accuracy (d’) | E2 | −0.601 (1.57) | −1.34 (1.45) | −1.25 (1.28) | ||
| PLC | −0.22 (1.43) | −0.64 (1.71) | −1.13 (1.6) | |||
| 2-Back accuracy (d’) | E2 | −0.164 (1.41) | −0.596 (1.45) | −0.67 (1.43) | ||
| PLC | −0.065 (1.35) | −0.37 (1.64) | −0.355 (1.33) | |||
| 3- Back accuracy (d’) | E2 | −0.136 (1.37) | −0.38 (1.41) | −0.78 (1.24) | ||
| PLC | 0.148 (1.08) | −0.28 (1.03) | −0.27 (1.26) | |||
| SRT | Immediate recall (number | E2 | −4.45 (14.77) | −10.4 (14.38) | −12.5 (15.5) | |
| correct) | PLC | −5 (10.81) | −9.17 (13.9) | −12.67 (9.77) | ||
| Delayed recall (number | E2 | −0.4 (3.2) | −1.45 (3.17) | −2.3 (2.3) | ||
| correct) | PLC | −0.67 (2.7) | −1.44 (3.03) | −2.39 (2.85) | ||
| Recall consistency | E2 | −6 (15.13) | −15.35 (14.94) | −16.6 (16.24) | ||
| PLC | −4.6 (13.16) | −10.22 (18.05) | −15.06 (13.37) | |||
| Recall failure | E2 | 1.4 (12.4) | 3.55 (12.25) | 5.25 (13.81) | ||
| PLC | 4.67 (8.3) | 5.94 (7.92) | 7.28 (5.89) |
Note: Numbers represent difference scores of challenge day (active drug - placebo), with standard deviations in the parentheses. Significant effects of estrogen treatment are indicated. See text for challenge drug effects.
Abbreviations: CFF, Critical Flicker Fusion; CRT, Choice Reaction Time task; E2, Estradiol; MECA, Mecamylamine; PLC, Placebo; SCOP, Scopolamine; SRT, Selective Reminding Test.
p < 0.05
a
Main effect of estrogen treatment in the MECA analysis for Ascending (Hz) on the CFF, p = 0.05.
b
Main effect of estrogen treatment in the SCOP + MECA analysis for recognition RT on the CRT.